Distribution of Kell phenotype among pregnant women in Sokoto, North Western Nigeria by Osaro, E et al.




Distribution of Kell phenotype among pregnant women in Sokoto, North Western 
Nigeria 
 
Erhabor Osaro1,&, Malami Aisha Ladan1, Isaac Zama1, Yakubu Ahmed2, Hassan Mairo2 
 
1Department of Haematology and Transfusion Science, Faculty of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, 
Nigeria, 2Department of Obstetrics and Gynaecology Usmanu Danfodiyo University, Sokoto, Nigeria 
 
&Corresponding author: Erhabor Osaro, Department of Haematology and Transfusion Science, Faculty of Medical Laboratory Science, Usmanu 
Danfodiyo University, Sokoto, Nigeria 
 
Key words: Kell phenotype, pregnant women, Nigeria 
 
Received: 19/05/2014 - Accepted: 15/01/2015 - Published: 26/08/2015 
 
Abstract  
Introduction: Kell antigen is highly immunogenic and is the common cause of antibody production in mismatched blood transfusions, haemolytic 
transfusion reaction (HTR) and maternal alloimmunization, which causes severe anaemia in neonates. The aim of this study is to determine the 
prevalence and ethnic variation of the Kell phenotype among pregnant women in Sokoto, Nigeria. Methods: Kell antigen status of 150 pregnant 
women aged 18-45 years and mean age 27.19 ±4.69 years attending antenatal clinic in UDUTH Sokoto Nigeria was determined using the 
conventional tube method and anti-Kell reagents (Lorne Laboratories, UK). Results: Among the 150 subjects studied, 3 (2.0%) of subjects were 
positive and 147 (98.0) were negative for K antigen. Of the 150 pregnant subjects; 32 (21.3%) were primigravidae while 118 (78.7%) were 
multigravidae. Kell phenotype was more prevalent among primigravidae (3.1%) compared to multigravidae (1.7%) women. The distribution of Kell 
phenotype among the pregnant subjects was compared based on ethnicity. The prevalence of Kell antigen was significantly higher among the 
Hausa ethnic group (3.2%) compared to other ethnic groups which indicated zero prevalence (p=0.001). Kell negative phenotype was ≥ 96.8% 
among all the ethnic groups. Conclusion: Our observed prevalence of Kell phenotype is consistent with previous studies among Blacks and Asians 
but significantly lower than values observed in previous studies among Caucasians. We recommend that all pregnant women should be screened 
for the presence clinically significant red cell antigens including Kell antigen on their first antenatal visit. Kell negative red cell should be routinely 
provided for all pregnant women and women with child bearing potential to reduce the risk of Kell-associated HDFN. There is need to introduce 
routine screening of pregnant women for clinically significant red cell antibodies to facilitate the effective management of HDFN as well as prevent 
HTR. There is also need for sustained health education of pregnant women in the area to encourage early booking for antenatal care. 
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Introduction 
 
The Kell blood group system is complex and has many antigens 
which are highly immunogenic. These antigens particularly KEL 1 
are second to Rhesus D as a cause of Haemolytic Disease of the 
Foetus and New-born (HDFN) [1]. Antibodies that target Kell 
antigens can cause HDFN, as well as Haemolytic Transfusion 
Reactions (HTR) [2]. Anti-Kell related HDFN causes severe foetal 
anaemia as maternal anti-Kell target foetal RBC precursors, 
suppressing the foetal production of RBCs [3, 4]. The Kell blood 
group system was discovered in 1946 and was named after Mrs. 
Kelleher, a patient who had anti-Kell antibodies and whose baby had 
HDFN. The Kell blood group system is important in transfusion 
medicine and HDFN and is considered to be one of the major 
human blood group antigens. Antibodies produced against Kell 
antigens are predominantly IgG and can cross the placental barrier, 
does not bind complement and therefore causes is extravascular 
haemolysis. KEL is highly polymorphic, has two major codominant 
alleles, k and K, which result from a SNP (698C→T) and the 
corresponding k and K antigens differ by a single amino acid change 
[4-6]. Individuals without Kell antigens (K0) who have formed an 
antibody to a K antigen must be transfused with blood from donors 
who are also K0 to prevent severe haemolytic transfusion reaction 
[2, 7]. Kell isoimmunisation is the third most common cause of 
HDFN after Rh and ABO. Anti-Kell causes severe foetal anaemia by 
suppressing foetal RBC synthesis [8]. Anti-Kell is an important cause 
of HDFN and tends to occur in mothers who have had several Kell 
incompatible blood transfusions in the past and in mothers who 
have been sensitized to the Kell antigen during previous 
pregnancies. HDFN -associated anaemia is caused by the ability of 
anti-K to cause the suppression of foetal production of RBCs [9]. 
Unlike Rh and ABO, Kell antigens are expressed on the surface of 
RBC precursors, and anti-K promotes the immune destruction of K+ 
erythroid early progenitor cells by macrophages in the foetal liver 
rather than only mature foetal RBCs [10]. The RBC precursors do 
not contain haemoglobin and thus less bilirubin is released during 
the haemolysis, and jaundice in the new-born period is less common 
in Kell-related HDFN [11]. There is paucity of data on the 
prevalence of Kell phenotype among pregnant women in Sokoto, 
Nigeria. The risk of anti- Kell- related HDFN in Sokoto is unknown. 
Therefore the present study is aimed at determining the prevalence 
and ethnic variations of the Kell phenotype among pregnant women 
in Sokoto, Nigeria. Data generated will help improve the obstetrics 
care offered to pregnant women in the area and may help justify 
the need to routinely screen pregnant women in the area for 
clinically significant red cell antigens. Findings from this study will 
also help blood bank in the area to stock optimum levels of Kell 
negative units for use among pregnant women and women who are 
of child- bearing age and are Kell antigen negative as well as those 
who are positive for anti-Kell antibodies that require antigen 







Study site: the selected area for this study is Usmanu Danfodiyo 
University Teaching Hospital (UDUTH) which is located in Wamakko 
Local Government within Sokoto Metropolitan city in Sokoto State. 
Sokoto State is located in the extreme Northwest of Nigeria, near 
the confluence of the Sokoto River and Rima River. With an annual 
average temperature of 28.30c (82.9 0F). Sokoto is, on the whole, a 
very hot area. However, maximum day time temperatures are for 
most of the year generally under 40 0C (104.0 0F). The warmest 
months are February to April when daytime temperatures can 
exceed 45 0C (113.0 0F). The rainy season is from May to October 
during which showers are a daily occurrence. There are two major 
seasons, wet and dry which are distinct and are characterized by 
high and low malarial transmission respectively. Report from the 
2007 National Population Commission indicated that the State had a 
population of 3.6 million [12]. 
  
Study subjects and design: this case study included 150 
consecutively- recruited pregnant women vising the antenatal clinic 
in Usmanu Danfodiyo Hospital Sokoto. Subjects were aged 18-45 
years with mean age of 27.19 ±4.69 years. Blood samples were 
analysed for their Kell antigen status. Verbal informed consent was 
obtained from all study subjects. The study was approved by the 
ethical committee of Usmanu Danfodiyo University Teaching 
Hospital, Sokoto, Nigeria. 
  
Inclusion criteria: all consecutively-recruited, consenting and 
confirmed pregnant (by a consultant obstetrician) women aged 15-
45 years visiting the antenatal clinic of Usmanu Danfodiyo University 
Teaching Hospital (UDUTH) Sokoto were included in this study. 
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Exclusion criteria: the following were excluded from this study; 
non-pregnant women, non-consenting pregnant women, women 
who have had a red cell transfusion in the last 4 months and 
women who have had a recent stem cell or bone marrow transplant. 
  
Study site and participating hospital: study will be conducted 
in the service laboratory of Usmanu Danfodiyo University Teaching 
Hospital (UDUTH) Sokoto, Nigeria. The hospital is a tertiary health 
facility rendering quality healthcare services to the people of Sokoto 
State and the neighbouring states of Zamfara and Kebbi State. 
  
Sample collection and testing: three millilitres of blood sample 
was drawn aseptically with disposable plastic syringe from the 
median antecubital vein for all the subjects into dipotassium 
ethylenediamine tetracetic acid (K2EDTA) blood containers. 2-3% 
suspension of washed red cells from each study subjects was 
prepared in low ionic strength solution. Lorne Laboratories (UK) 
anti-Kell reagents were reacted with red cell suspension from each 
subject. The Lorne anti-Kell reagent will cause direct agglutination 
(clumping) of cells that carry K antigen. No agglutination generally 





In this study, the Kell phenotype of 150 pregnant women aged 18-
45 years and mean age 27.19 ±4.69 years attending antenatal clinic 
in UDUTH Sokoto Nigeria was determined. Among the 150 subjects 
3(2.0%) of subjects were positive for K and 147(98.0) were 
negative for K antigen. Table 1 shows the prevalence of Kell 
antigen among subjects. 
  
Distribution of Kell antigen based on parity 
  
Of the 150 subjects 32 were primigravidae (%) while 118 were 
multigravidae. Of the 32 primigravidae, 1 woman (3.1%) was Kell 
positive while 31 (96.9) were Kell negative. Also 2 out of the 118 
multigravidae women (1.7%) were Kell positive while 116 (98.3%) 
were Kell negative. Table 2 show the distribution of K negative 





Distribution of subjects based on ethnicity 
  
The distribution of Kell phenotype among the pregnant subjects was 
compared based on ethnicity. The Hausa ethnic group constituted 
the most predominant ethnic groups 94(62.7%) compared to 
20(13.3%), Igbo 20(13.3%), Fulani 13(8.7%), others minority 
ethnic groups 13 (8.7%) and Yoruba 10(6.7%). The prevalence of 
Kell phenotype was significantly higher among the Hausa ethnic 
group (3.2%) compared to other ethnic groups that indicated zero 
prevalence (p=0.001). Kell negative phenotype was ≥ 96.8% 
among all the ethnic groups.Table 3 shows the prevalence of Kell 





Information about the prevalence of blood group antigens in a 
population is useful for providing better blood transfusion services 
and in the effective and evidenced-based management of HDFN. 
This research work was carried out to determine the prevalence of 
Kell phenotype among pregnant women in Sokoto, North Western 
Nigeria. Among the pregnant women studied, we observed a Kell 
antigen prevalence of (2%). Our finding is consistent with previous 
report by Lamba and colleagues [13] who observed a Kell antigen 
prevalence of 2.8% among their cohort of 1,000 healthy and regular 
repeat blood donors in India. Our finding is also consistent with a 
previous report by Chaudhary and colleagues [14] among North 
Indian blood donors which reported a Kell prevalence of 1.92%. 
Similarly, Ugboma and Nwauche [15] in Port Harcourt investigated 
the prevalence of Kell antigen among their patients and reported a 
Kell antigen prevalence of 2%. Our observed prevalence of 2.0% is 
however lower than a prevalence of 5.56% observed by Thakral and 
colleagues [16] among North Indian blood donors. Our observed 
prevalence is also lower than that previously reported among 
Caucasians (9%) [17-19]. Our observed Kell prevalence is also 
lower than a 3.5% prevalence obtained by Makroo and colleagues 
[20] among their cohort of 3073 blood donors in India. Racial 
differences seem to exist in Kell blood group antigen distributions 
[13, 19]. A study of randomly selected 123 regular Maldivian blood 
group O blood donors who were phenotyped for Kell blood group 
antigen indicated a prevalence of 5.7% [21]. Similarly a previous 
report among 115 blood donors who were investigated in South 
Gujarat, India for extended antigen typing, reported no Kell 
phenotype [22]. Also, a previous study by Lin and colleagues [23] 
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(1988) among Chinese subjects in Taiwan indicated a zero percent 
Kell prevalence. The prevalence of K phenotype among Senegalese 
is 0.5% [24]. A previous report on the prevalence of Kell blood 
group antigen in the Bengalee population observed a Kell phenotype 
prevalence of 0.8% [25]. Similarly, evaluation of Kell blood group 
antigen frequencies among Macedonian population by Makarovska-
Bojadzieva and colleagues [26] indicated a Kell prevalence of 
0.25%. 
  
Kell blood group system is the next most clinically significant after 
the ABO and Rhesus blood group system [27]. Antibodies to the Kell 
antigen have been incriminated in HDFN and in haemolytic 
transfusion reactions [28-30]. Anti-K typically presents as IgG class 
alloantibody. Individuals lacking a specific Kell antigen may develop 
antibodies against Kell antigens when transfused with blood 
containing that antigen. This is particularly true for the K antigen 
which shows a relatively high antigenicity and moderately low 
frequency in African populations. The Kell antibodies low molecular 
weight IgG antibodies and can pass through the placenta barrier 
and cause HDFN in foetus positive for the Kell antigen [31]. The 
alloantibodies, which frequently develop and are encountered during 
compatibility testing, are primarily against antigens related to Kell 
blood group system [28]. Antibodies directed against Kell antigens 
are implicated in cases of HTRs and HDFN, and are, therefore, 
regarded as clinically significant particularly if these react in the 
indirect antiglobulin test at 37°C [28, 32, 33]. It is vital to routinely 
determine the frequencies of the various blood group antigens 
among blood donors population particularly with regards to meeting 
the red cell transfusion-related needs of patients who have 
developed multiple alloantibodies. This information is necessary to 
predict the availability of blood units that lack the corresponding 
antigen(s). A review of the prevalence of antibodies associated with 
HDFN in reproductive age women revealed a marked decrease in 
the incidence of anti-Rh D and an increasing incidence of anti-K 
antibody in the US and in other developed countries [34]. Anti-K 
was detected with a frequency of 1.0% in a previous study [29] that 
investigated 500 pregnant women for clinically significant red cell 
antibodies in Port Harcourt, Nigeria. Anti-K related HDFN can be 
severe and there is evidence that anti-K can recognize K antigens 
expressed in the early stage of erythroid development in the foetal 
liver and can cause anaemia by suppressing erythropoiesis [34, 35]. 
A previous study investigated the prevalence of red cell antibodies 
among pregnant women in Sweden and observed eight hundred 
and twenty-one alloantibodies in 629 immunized pregnant women 
with 753 foetuses. An overall antibody incidence of 0.57% was 
observed which included 373 clinically significant antibodies found in 
261 mothers (0.24%). Multiple antibodies were present in 8.2% of 
all samples. Anti-K HDFN was reported in16 Kell-positive babies out 
of whom three required phototherapy and one required exchange 
transfusions [36]. 
  
Our finding underscores the importance of routine screening of 
pregnant women for clinically red cell antigens [37]. The phenotype 
of clinically significant red cell antigens on donor's red cells is 
important particularly if the blood is intended for transfusion to 
patients with alloantibodies to facilitate the transfusion of red cells 
that are negative for the antigens to which patient's antibodies are 
specific. Routine determination of clinically significant red cell 
antigens facilitates the planning and running of an efficient blood 
transfusion service and better management of HDFN. First-trimester 
screening of pregnant women enables timely identification and 
treatment of HDFN. Severe HDFN, caused by antibodies other than 
anti-D, is associated with anti-K, anti-c, and to a lesser extent with 
other Rh-alloantibodies [38]. The knowledge of clinically significant 
red cell antigens that are known to cause HDFN, HTR and shortened 
survival of red cell is important and can help in the prevention and 
appropriate management of HDFN as well as optimize transfusion 
among transfusion- dependent patients (sickle cell disease, 
thalassemia, haematological oncology, myelofibrosis myelodysplasia 
and aplastic anaemia) particularly those that have developed 
alloantibodies against clinically significant red cell antigens [39]. 
One strategy to decrease alloimmunization in transfusion dependent 
women of child bearing age is provision of phenotype matched RBCs 
for C, E, and K antigens [40]. Individuals lacking the Kell antigen 
may develop antibodies against Kell antigen when transfused with 
Kell positive red cells. These antibodies can potentially cause the 
destruction of Kell positive red cells in future transfusions. Similarly 
pregnant women who are Kell negative can be sensitized by feto 
maternal haemorrhage associated with pregnancy involving a Kell 
positive foetus [41]. 
  
Pregnant women with K antibodies will need to be effectively 
managed by a gynaecologist to reduce the risk of HDFN. Effective 
management will involve checking the paternal sample for their Kell 
antigen status. If the husband is Kell positive, there may be need to 
determine the foetal Kell genotype using maternal plasma at 20 
weeks gestation [42]. If the foetal Kell genotype is positive, the 
anti-K titre will need to be monitored every 4 weeks until 28 weeks 
gestation and every 2 weeks thereafter. There is a high risk of 
HDFN if the anti-Kell titre is 32 or greater or if there has been a 
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significant rise since last titration [43, 44]. At delivery it is important 
to monitor baby's blood group, direct antiglobulin test, haemoglobin 
and bilirubin [45]. Severely jaundiced baby may be managed with 
phototherapy or with exchange blood transfusion to prevent 
Kernicterus. The pathogenesis of HDFN caused by anti-K differs 
from anti-D. This is because anti-Kell associated HDFN is much 
harder to predict, as there is little association between anti-K titre 
and severity of the disease and anti-K associated HDFN is linked 
with lower concentrations of amniotic fluid bilirubin than in anti-D 
HDFN of corresponding severity. Also postnatal hyperbilirubinaemia 
may not present in babies with anaemia caused by anti-K. There is 
decreased reticulocytosis and erythroblastosis in the anti-K disease. 
Foetal anaemia in anti-K HDN is due to suppression of 
erythropoiesis. The Kell glycoprotein emerges on erythroid 
progenitors, by macrophages in the foetal liver, before they develop 
into haemoglobinized erythroblasts [46]. As RBC precursors contain 
no haemoglobin, the release of bilirubin is reduced during 
haemolysis, therefore jaundice is not as common, but severe 
anaemia may occur [3]. This is supported by in vitro studies which 
have shown that antibodies to Kell inhibit growth of KEL 1 
progenitor cells. In order to prevent HDFN, it is necessary for the 
detection of the foetal KEL 1 gene [1]. In pregnant women with 
anti-KEL1 and who have a partner with KEL 1 and 2, prediction of 
KEL1 phenotype from tests on foetal DNA allows obstetricians to 
adjust management of the pregnancy based on whether the foetus 





Our study indicates that blood group antigens can be distributed 
differently within different nationalities. Our observed prevalence of 
Kell phenotype is consistent with previous studies among Blacks and 
Asians but significantly lower than values observed in previous 




We recommend that all pregnant women should be screened for the 
presence clinically significant red cell antigens including Kell blood 
group antigens on their first antenatal visit. There is need to 
introduce routine screening of pregnant women in Sokoto Nigeria 
for clinically significant red cell antibodies to facilitate the 
management of HDFN as well as prevent HTR by enabling the 
selection of antigen negative red cells for women who have 
alloantibodies and require a red cell transfusion. Kell negative red 
cell should be routinely provided for all pregnant women with child 
bearing potential to reduce the risk of Kell-associated HDFN. There 
is also need for sustained health education of pregnant women in 
the area to encourage early booking for antenatal care and 




This study had some limitations. Firstly the sample size for this 
study was relatively small compared to the huge population of the 
North West zone in particular and the Nigeria nation in general. The 
prevalence obtained in this study gives an estimate on the 
frequencies of the Kell phenotype among pregnant women in 
Sokoto, North West, Nigeria. Cost implications as well as access to 
reagents was a limiting factor that affected the number of subjects 
included in this study. There is need for a nationwide study to 
determine the prevalence of Kell blood group antigens among 
Nigerians. Secondly, we used the conventional manual tube method 
in the screening of our cohort of pregnant women for Kell 
phenotype. Some previous reports which utilized more sensitive 
automated testing instrument using commercial antisera and gel 
card methods. Evidenced -based best practices in most developed 
countries indicates that the gel and glass beads-based card method 
has several advantages over the conventional tube method ; 
paediatric friendly because they require small volume of patient 
specimen, unlike with tube methods, no washing of the antiglobulin 
is required, it is more standardized and does not require the use of 
subjective red cell suspension preparation required with tube 
testing, results are more objective (clear, eye and analyser 
readable) and does not require use of microscopes which is a 
requirement in tube testing, it is easy to automate unlike 
conventional tube method and thus very useful for high throughput 
laboratories. It also facilitates large batch testing with no risk of 
possible mix-up of patient sample common with tube testing and it 
is more sensitive and specific and has the capacity to detect very 
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Table 1: Prevalence of Kell antigen among subjects 
Antigen Number Tested Number Kell positive % Kell positive Number Kell negative % Kell negative 
Kell 150 3 2.0 138 98.0 
 
 
Table 2: Distribution of K negative phenotype based on parity 
Parity Number Tested K Positive % K  Positive K negative %  K egative p-value 
Primigravidae 32 1 3.1 31 96.9 
0.001 











% Kell positive Number K negative % Kell negative p-value 
Hausa 94 3 3.2% 91 96.8% 
0.001 
Fulani 13 0 0 13 100% 
Yoruba 10 0 0 10 100% 
Igbo 20 0 0 20 100% 
Others 13 0 0 13 100% 
  
 
